Bausch + Lomb (NYSE:BLCO) Announces Earnings Results

Bausch + Lomb (NYSE:BLCO) announced its earnings results on Wednesday. The company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.35 by ($0.03), Zacks reports. Bausch + Lomb had a negative net margin of 6.13% and a positive return on equity of 2.42%. During the same period in the previous year, the business earned $0.25 EPS. The company’s revenue for the quarter was up 9.8% compared to the same quarter last year.

Here are the key takeaways from Bausch + Lomb’s conference call:

• Reported record Q4 revenue of $1.405 billion and full‑year revenue of $5.101 billion, with Q4 Adjusted EBITDA of $330 million (up 27%) and a 23.5% EBITDA margin, highlighting strong operating leverage.
• 2026 guidance calls for full‑year revenue of $5.375–$5.475 billion (5%–7% constant‑currency growth) and Adjusted EBITDA of $1.0–$1.05 billion, implying continued margin expansion toward the company’s multi‑year targets.
• MIEBO drove blockbuster growth (FY revenue $316 million, Q4 $112 million, prescriptions >2 million) and management now sees peak sales potential exceeding $600 million, underpinning dry‑eye momentum.
• Pipeline and R&D milestones progressed: CE Mark submission for the Silera femtosecond laser expected soon and a first external study of a new bioactive contact‑lens material met expectations, keeping a 2028 launch timeline on track but still subject to further trials.
• Surgical business recovery post‑enVista recall: company says it returned to prior market levels ahead of plan, with premium IOLs up ~20% in Q4, supporting higher‑margin mix in implantables.

Bausch + Lomb Stock Down 3.1%

Bausch + Lomb stock opened at $17.19 on Wednesday. The firm has a 50 day simple moving average of $17.02 and a 200 day simple moving average of $15.80. The company has a current ratio of 1.51, a quick ratio of 0.98 and a debt-to-equity ratio of 0.76. Bausch + Lomb has a 1-year low of $10.45 and a 1-year high of $17.91. The firm has a market capitalization of $6.09 billion, a price-to-earnings ratio of -19.57, a P/E/G ratio of 0.99 and a beta of 0.61.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on BLCO shares. Raymond James Financial restated an “outperform” rating and set a $19.00 price objective (up previously from $18.00) on shares of Bausch + Lomb in a report on Thursday, October 30th. Wall Street Zen raised shares of Bausch + Lomb from a “hold” rating to a “buy” rating in a research report on Saturday, November 1st. Stifel Nicolaus lifted their price target on shares of Bausch + Lomb from $14.00 to $15.00 and gave the stock a “hold” rating in a report on Tuesday. HC Wainwright increased their price objective on Bausch + Lomb from $16.00 to $17.00 and gave the company a “buy” rating in a report on Friday, October 31st. Finally, Evercore set a $18.00 target price on Bausch + Lomb and gave the stock an “in-line” rating in a research report on Monday, January 5th. Four investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $17.42.

Hedge Funds Weigh In On Bausch + Lomb

Hedge funds have recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd raised its stake in shares of Bausch + Lomb by 104.1% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 2,227 shares of the company’s stock valued at $38,000 after purchasing an additional 1,136 shares during the period. Northwestern Mutual Wealth Management Co. grew its holdings in Bausch + Lomb by 729.3% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 2,322 shares of the company’s stock valued at $30,000 after buying an additional 2,042 shares in the last quarter. Wells Fargo & Company MN increased its position in shares of Bausch + Lomb by 31.2% during the fourth quarter. Wells Fargo & Company MN now owns 5,903 shares of the company’s stock valued at $101,000 after buying an additional 1,403 shares during the period. Focus Partners Wealth bought a new stake in shares of Bausch + Lomb during the third quarter valued at about $170,000. Finally, JPMorgan Chase & Co. purchased a new stake in shares of Bausch + Lomb in the second quarter worth about $200,000. 11.07% of the stock is currently owned by hedge funds and other institutional investors.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.